our response
to the crisis

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. We were created to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live.

GARDP was established in 2016 by the World Health Organization (WHO) and Drugs for Neglected Diseases initiative (DNDi) to deliver on the Global Action Plan on Antimicrobial Resistance.
After five years in operation, GARDP has already built a pipeline to tackle sexually transmitted infections as well as infections in hospitalized adults and children, including newborns with sepsis (a bloodstream infection). We have formed over 60 partnerships in 22 countries that span governments, the biomedical and pharmaceutical industries, research institutions, non-profits, and civil society. 

GARDP bridges the gap between innovation and access by focusing on developing candidates in late-stage clinical development. This requires identifying the barriers to access and finding innovative ways to overcome them. We are also exploring ways to ensure there is a viable market and sustainable supply of treatments in the long-term. 

To tackle the growing antibiotic resistance crisis, GARDP has set the 5 BY 25 goal, which seeks to deliver five new treatments by 2025 for drug-resistant infections that pose the greatest threat to health and economic security.

“The COVID-19 pandemic has brought into sharp focus the impact of pandemics and the importance of preparedness. It has demonstrated that addressing the silent pandemic of drug-resistant infections can only be achieved through greater international cooperation and investment. As host country, Switzerland recognizes the major role GARDP plays at the global level in the fight against antibiotic resistance.”

Alain berset
Federal Councillor, Head of the Federal Department of Home Affairs (FDHA), Switzerland

our Vision

All infections are treatable for everyone, everywhere.

Our Mission

We bring together the public and private sectors to develop new treatments for bacterial infections. We ensure responsible and sustainable access, addressing the public health impact of antibiotic resistance.

Our Focus

  • Bacteria on the WHO
    priority pathogen list
  • Diseases and populations
    disproportionally affected
    by drug resistance
  • Late-stage clinical
    development and access



We are proud of the progress we made in 2020 towards building an antibiotic portfolio and achieving our 5 BY 25 goal: to deliver five new treatments to tackle drug-resistant infections that pose the greatest threat to health by 2025.

1. Completed

a landmark observational study on neonatal sepsis and finalised a clinical study report on the pharmacokinetic clinical trial assessing the safety and dosing of fosfomycin in newborns.

2. Identified

one potential antibiotic combination of fosfomycin-amikacin to treat neonatal sepsis.

3. Signed

first agreement of GARDP’s Serious Bacterial Infections programme and started the first project to bring a new drug to market.

4. Continued

patient enrolment in the US and activated a new site in The Netherlands, as part of our phase 3 trial of a new treatment for gonorrhoea.

5. Organised

17 REVIVE webinars and launched a new online Antimicrobial Encyclopaedia.

6. Screened

over 24,000 compounds from five different partners. Daiichi Sankyo joined the GARDP-led Antimicrobial Resistance Screening Consortium alongside Eisai and Takeda.

Activity Report 2020

The 2020 Activity Report shows GARDP’s progress and promise in the fight against the most serious drug-resistant infections. It also demonstrates why more partnerships and investment are critical to address the growing threat of antibiotic resistance and achieve the Sustainable Development Goals.

Download full report

Sign up to our newsletter to stay connected


ⓒ GARDP Foundation, 2021
Design Enigma